• EN - English
  • PT - português
Parliamentary question - E-006775/2020Parliamentary question
E-006775/2020

    Terms and conditions of the agreements concluded with pharmaceutical companies/consortia for the development and purchase of COVID‑19 vaccines (III)

    Question for written answer  E-006775/2020
    to the Commission
    Rule 138
    João Ferreira (GUE/NGL)

    In its communication on the ‘EU Strategy for COVID‑19 vaccines’, the European Commission proposes a support framework for the pharmaceutical industry involving an ‘insurance policy, which transfers some of the risk from industry to the public authorities’. This is because the assumption is that the vaccines in development, which have been secured under Advance Purchase Agreements (APAs), may suffer a high rate of failure in their development, with ‘a very real risk’ that they will not be successful.

    It also states that ‘the liability for the deployment and use of the vaccine, including any specific indemnification required by a given APA will remain with the purchasing Member States’. However, under the EU’s own product liability rules, it should be the companies that are liable.

    Can the European Commission tell me whether the agreements concluded with the pharmaceutical companies/consortia provide for the recovery of funding granted if nothing comes of the agreement?

    Can the Commission be more specific about how the ‘risk sharing’ that it mentions will be achieved?

    Exactly what concessions in terms of product liability have been made to the companies/consortia with which APAs have been concluded?

    Last updated: 21 December 2020
    Legal notice - Privacy policy